

Atty Docket No. 023070-087120US

PTO FAX NO.: 1-703-872-9306

ATTENTION: Examiner Patterson, Charles L., Jr.
TELEPHONE NO.: 1-571-272-0936

Group Art Unit 1652

**OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Patterson, Charles L., Jr.**

Examiner Patterson: Per your request yesterday, attached is a copy of the sequence listing and Communication Under 37 CFR 1.821-1.825.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of VREELAND and NG, Application No. 09/840,762, filed April 23, 2001 for RECOMBINANT VANADIUM HALOPEROXIDASES AND THEIR USES are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

Communication Under 37 C.F.R. §§ 1.821-1.825 and Amendment After Allowance Under 37 C.F.R. § 1.312(a) - 5 pages; paper copy of Sequence Listing - 9 pages

Number of pages being transmitted, including this page: 15

Dated: August 27, 2004

Karen Karlin
Karen Karlin

*PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300*

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: 415-576-0200
Fax: 415-576-0300
60296113 v1

RECEIVED
CENTRAL FAX CENTER

AUG 27 2004

I hereby certify that this correspondence is being faxed to 1-703-872-9306
on August 27, 2004.

TOWNSEND and TOWNSEND and CREW LLP

By: Karen KarlsonPATENT
Attorney Docket No.: 02307O-087120US
Client Ref. No.: 1998-005-2
Customer No.: 20350

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VREELAND and NG

Application No.: 09/840,762

Filed: April 23, 2001

For: RECOMBINANT VANADIUM
HALOPEROXIDASES AND THEIR
USES

Confirmation No. 5972

Examiner: Patterson, Charles L., Jr.

Art Unit: 1652

COMMUNICATION UNDER37 C.F.R. §§ 1.821-1.825ANDAMENDMENT AFTER ALLOWANCEUNDER 37 CFR § 1.312(a)

Mail Stop Issue Fee
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

In response to the Examiner's request via telephone on August 26, 2004, and in order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit that the computer-readable form in the instant application is identical with that filed in Application No. 09/151,189, submitted May 21, 1999. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer-readable form filed in Application No. 09/151,189 as the computer-readable form for the instant application. A paper copy of the Substitute Sequence Listing from Application No. 09/151,189 is submitted herewith. The information in the paper copy of the

Appl. No. 09/840,762
Amtd. dated August 27, 2004
Amendment After Allowance for Sequence Listing

PATENT

Substitute Sequence Listing is identical to that which is in the computer readable form submitted on September 18, 2001, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 5 of this paper.